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Background
Cell adhesion molecules (CAMs) expressed on hematopoietic progenitor cells (HPCs), 
endothelial cells, and stromal cells play a pivotal role in the mobilization of CD34+ cells. 
Herein, we conducted a non-randomized peripheral blood stem cell (PBSC) mobilization 
study aimed to compare the potential differences in the expressions of several CAMs and 
chemokines on CD34+ cells obtained from bone marrow aspirate before and after HPC 
mobilization from patients with hematologic malignancies and healthy donors.
Methods
Three-color cytofluorometric analysis was used to compare the expressions of CAMs and 
chemokines in the bone marrow before and after mobilization. 
Results
For all studied groups, CAM expression among those with good and poor yields of CD34+ 
cells was significantly correlated with VCAM-1 (P=0.007), CD44 (P=0.027), and VLA-4 
(P=0.014) expressions. VCAM-1 (P=0.001), FLT-3 (P=0.001), CD44 (P=0.011), VLA-4 
(P=0.001), and LFA-1 (P=0,001) expressions were higher before HPC mobilization than 
after HPC mobilization. By contrast, the expression of CXCR4 significantly varied before 
and after mobilization only among those with successful PBSC mobilization (P=0.002).
Conclusion
We attempted to identify particular aspects of CAMs involved in CD34+ cell mobilization, 
which is a highly complex mechanism that involves adhesion molecules and matrix 
metalloproteases. The mechanism by which CD34+ cell mobilization is activated 
through proteolytic enzymes is not fully understood. We believe that CXCR4, VLA-4, 
CD44, and VCAM-1 are the most important molecules implicated in HPC mobilization, 
particularly because they show a correlation with the yield of CD34+ cells collected via 
large volume leukapheresis.
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INTRODUCTION
Peripheral blood stem cells (PBSC) have become the main 
source for autologous and allogeneic marrow transplantation 
because they are associated with earlier neutrophil and plate-
let engraftment and shorter hospitalization than bone mar-
row (BM) stem cells [1, 2]. A substantial amount of CD34+ 
cells can be mobilized from the BM into the peripheral 
blood (PB) by hematopoietic growth factors alone or in com-
bination with cytotoxic agents and the partial CXC chemo-
kine receptor-4 antagonist, plerixafor [2-4]. The prerequisite 
for autologous stem cell transplantation (ASCT) is successful 
and adequate stem cell mobilization and collection. 
Depending on the criteria, failure rates range from 5% to 
40% [4, 5]. Despite the high success rate of PBSC trans-
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Table 1. Characteristics of the patients and donors.
Characteristics Value
N of individuals 48
Median age, years (range) 45 (19–64)
Gender (female/male) 20/28
Diagnosis
   Non-Hodgkin lymphoma 16
   Hodgkin’s disease 04
   Multiple myeloma 16
   PBPC donors 12
Mobilization regimens
   G-CSF (donors) 12
   G-CSF+chemotherapy (patients) 36
Non-Hodgkin’s lymphoma grade 16
   High 14 DHAP (6), ICE (6), 
  Cy+VP-16 (1), Cy (1)
   Low 02 Cy (1), ICE (1)
Hodgkin’s lymphoma 04 ICE (3), DHAP (1)
Multiple myeloma 16 Cy+VP-16 (2), Cy (14)
Total 48
PBPC, peripheral blood progenitors cells.
G-CSF, granulocyte-colony stimulating factor (10 μg/kg/day); 
Cy-Cyclophosphamide (5 g/m2); Cy+VP-16 Cyclophosphamide (5 
g/m2)+VP-16 (400 mg/m2).
ICE, Ifosfamide 5,000 mg/m2 carboplatin AUC=5 (max. 800 mg); 
e, 100 mg/m2.
DHAP, Cisplatin 100 mg/m2; cytarabine, 2,000 mg/m2; Dexa-
methasone 40 mg.
plantation, the specific mechanisms involved in PBSC mobi-
lization and homing are unclear [4]. The efficacy of mobi-
lization is related to several factors, including the number 
of prior therapies and the mobilization protocols [2, 4, 6]. 
The number of CD34+ cells in the PB before PBSC collection 
is correlated with the yield of CD34+ cells in the apheresis 
product (AP) and it is used to determine when to begin 
collection [1-3]. However, specific tools that can be applied 
before initiating mobilization regimens to predict the yield 
of CD34+ cells are still unavailable. Adhesive interactions 
between the CD34+ hematopoietic progenitor cells (HPCs) 
and the cellular and matrix components of the BM environ-
ment are involved in the mobilization [7-9]. Under 
steady-state conditions, HPCs are mainly in close contact 
with the BM microenvironment. Various cell adhesion mole-
cules (CAMs) and chemokines are expressed on HPCs, in-
cluding β1 integrins, such as very late antigen-4 (VLA-4) 
(CD49d/CD29) and VLA-5 (CD49e/CD29); β2 integrins, such 
as leukocyte function antigen-1 (LFA-1) (CD11a/CD18); se-
lectins, such as L-selectin (CD62L); and members of the 
immunoglobulin super-family, such as intercellular adhesion 
molecule-1 (ICAM-1) (CD54), vascular cell adhesion mole-
cule-1 (VCAM-1) (CD106), and the chemokine CXCR4 re-
ceptor of stromal-derived factor-1 (SDF-1) and CD44, the 
major receptor of hyaluronic acid (HA) [7-15]. The inter-
action between VCAM-1, which is expressed in BM stromal, 
and the counter-receptor integrin VLA-4, expressed at the 
surface of HPCs, is critical to the homing and release of 
HPCs in the BM [11-12]. A second pathway implicated in 
the trafficking of HPCs is the CXCR4/SDF-1 chemotactic 
axis [13, 14]. Plerixafor selectively disrupts the adhesion 
between CXCR4 on CD34+ cells and its ligand CXCL12, 
which is expressed by marrow stromal cells, thereby causing 
the release of marrow CD34+ cells into peripheral circulation 
[5, 13-15]. 
CD44 is important in cell migration in various normal 
and malignant cells. CD44 is a multifunctional and multi-
structural receptor with numerous isoforms. Standard CD44 
(CD44s), the smallest CD44 molecule, which lacks the entire 
variable region, is the most common isoform expressed on 
HPCs. The major ligand of CD44 is HA, an important compo-
nent of the extracellular matrix in many different organs, 
including the BM where it is produced by both stromal 
and hematopoietic cells. During granulocyte colony stimulat-
ing factor (G-CSF)-mediated mobilization, neutrophil de-
granulation occurs, leading to upregulation of the matrix 
metalloproteases, which in turn causes cleavage of CD44 
and a decrease in CD44 expression [16, 17].
FLT3 is a type III tyrosine kinase receptor expressed mainly 
by primitive hematopoietic cells. FLT3L, the ligand for this 
receptor, is also a transmembrane protein expressed on vari-
ous cells, including fibroblasts and T lymphocytes [18]. 
FLT3L is a stem-cell specific growth factor that expands 
and may also mobilize stem cells in mice after its admin-
istration for 10 days either as a single agent or in combination 
with other molecules, such as interleukin 8 (IL-8) and G-CSF 
[18-20]. 
The main objective of the present study is to compare 
the potential differences in the expressions of different CAMs 
and chemokines on CD34+ cells obtained from the BM before 
and after CD34+ cell mobilization. Possible differences in 
the behavior of CAMs between individuals with successful 
and those with failed mobilization were investigated. We 
also aimed to compare the behavior of CAMs and chemokines 
between donors and patients with lymphoma and multiple 
myeloma who have undergone CD34+ cell mobilization. 
MATERIALS AND METHODS
Patients
A non-randomized prospective protocol involving 48 in-
dividuals comprising 20 patients with lymphoma, 16 with 
multiple myeloma with indication for autologous trans-
plantation, and 12 healthy PBSC donors were included in 
this study. The study protocol was approved by the Ethics 
Committees of Universidade Federal de São Paulo (UNIFESP) 
and Santa Marcelina Hospital. Written informed consent 
was obtained from all patients, and the study was performed 
in accordance with the 1975 Helsinki Declaration. All pa-
tients were in complete or partial remission before 
mobilization. The clinical characteristics of these patients 
are summarized in Table 1. Among the patients with lympho-
mas, 13, 1, 2, and 4 had diffuse large B cell, anaplastic T 
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Table 2. Mobilization and collection efficacy.
Characteristics N 
N of individuals who underwent LVA   43
Patients/donors who did not undergo LVA 5/0
Mean N of CD34+ cell in the PB before 
LVA (range)
   101 (1–647)
      NHL      83 (1–211) 
      HL      45 (2–80) 
      MM    134 (1–647) 
Donors      43 (16–83) 
First day of apheresis after mobilization
Patients      15 (11–25) 
Donors        5 
      N of LGV        2 (1–4)
      1 apheresis   18
      2 apheresis   20
      3 apheresis     4
      4 apheresis     1
Mean total CD34+ cells collected 
(×106/kg) (range)
11.45 (1.65–85.52)
      Total patients 13.63 (1.65–85.52)
      NHL   9.35 (1.65–26.63) 
      HL   9.62 (3.98–14.53) 
      MM 18.14 (2.49–85.52) 
      Donors   5.82 (1.90–11.90)
Mean total nucleated cells collected 
(×108/kg) (range)
10.72 (2.53–23.51)
Patients   9.52 (2.53–23.51)
Donors 13.82 (5.04–20.59)
Total CD34+ cell yield (×106/kg)  
≥5 (patients/donors)      31 (25/6)
＜5 (patients/donors)      12 (6/6)
Abbreviations: LGV, lymphogranuloma venereum workup; LVL, 
large-volume leukapheresis; MM, multiple myeloma; NHL, 
non-Hodgkin’s lymphoma; NL, Hodgkin’s lymphoma.
cell, advanced follicular non-Hodgkin’s lymphoma, and re-
lapsed Hodgkin’s lymphoma, respectively. The 2 patients 
with non-Hodgkin’s lymphoma received 6 to 15 cycles of 
chemotherapy before mobilization, whereas those with 
Hodgkin’s disease received 9 to 12 cycles. Among the sixteen 
patients with multiple myeloma, thirteen had advanced dis-
ease (11, IIIA; 2, IIIB) and a monoclonal M component (12, 
IgG kappa; 2, IgG lambda; and 2, light chain) at diagnosis. 
They received 3 to 18 cycles of chemotherapy before 
mobilization. The mobilization procedures comprised che-
motherapy and subsequent G-CSF administration at a dose 
of 10 mg/kg daily for the patients and G-CSF alone for the 
donors. The type of mobilization regimen utilized for each 
disease and healthy donors are summarized in Table 2.
Characteristics of good and poor mobilization
The target optimal CD34+ cell yield at our institution 
is at least 5×106/kg recipient body weight, whereas a mini-
mum dose of at least 2×106/kg is recommended to proceed 
with ASCT. With this, we adopted the criterion to define 
successful mobilization for those individuals showing both 
CD34+ cell concentration of at least 15 cells per μL in the 
PB at the first day of the harvest and a yield of 5×106 per 
kg at most in up to 4 apheresis. 
PBSC collection
BM samples before and after HPC mobilization were ob-
tained from each patient and healthy donor. For all patients, 
PBSCs were mobilized after chemotherapy according to the 
specific treatment protocol. We administered 10 μ/kg G-CSF 
(granulokine, Roche, Brazil) subcutaneously twice daily after 
the white blood cell (WBC) count reached ≤1×109/L, and 
we maintained this level until the last day of large volume 
leukapheresis (LVL). The number of CD34+ cells in the PB 
was counted via flow cytometry to determine the PBSC 
overshoot for optimal collection. PBSC collection was started 
on the day the peripheral CD34+ cell count reached 15/μL 
or higher. The CD34+ cell were mobilized in healthy donors 
using 10 μg/kg/day G-CSF, administered subcutaneously dai-
ly, with the collection of cells on days 5 and 6. LVL was 
used to process more than 3 volumes of blood in a single 
session of apheresis [21]. 
Stem cell apheresis 
A temporary central venous access using a double-lumen 
catheter was obtained in 33 individuals in whom peripheral 
access was not possible. PBSCs were collected using a 
Cobe-Spectra cell separator (Gambro BCT, Lakewood, CO, 
USA) under manual control to obtain a final product with 
hematocrit of 2%. The patient’s and donor’s blood volumes 
were calculated using an automatic program incorporated 
in the separator according to the Nadler–Allen formula that 
considered weight, height, and gender [22]. Acid-citrate-dex-
trose (ACD-A, Hilex-Istar, Brazil) was used as an 
anticoagulant. To prevent hypocalcemia, calcium gluconate 
was systematically administered before and during 
collection. After LVL, all patients were evaluated via com-
plete blood count and biochemical tests. Metabolic abnormal-
ities were corrected and blood components were transfused 
as needed.
CD34+ cell count analyses 
The CD34+ cells in the PB, BM, and aliquots of LVL 
were analyzed via flow cytometry (FACSCalibur BD, San 
Jose, CA, USA) within 12 hours of collection. Only samples 
from BMA were subjected to the mononuclear cell (MNC) 
separation process via phycoll/Hypaque. All samples were 
incubated with double-marked conjugated monoclonal an-
ti-CD34/CD45 antibodies (CD34PE, Clone 8G12, Pharmingen/ 
CD45 FITC IgG1,anti-HLe-1, Pharmingen) for 20 minutes 
at 20oC after lysing solutions were added for 10 min. The 
samples were washed with buffer saline and fixed with 1% 
formaldehyde. Flow cytometric analyses were performed ac-
cording to the ISHAGE protocol, and the data were analyzed 
with Cell Quest software (Becton Dickinson, Franklin Lakes, 
NJ, USA) [22].
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Fig. 1. Representative flow cytometric scattergrams from bone marrow aspirate specimens after HPC mobilization showing a 3-color 
cytofluorometric analysis of the expression of adhesion molecule antigens on CD34+ cells population. (A) CD34+ cells are painted in the 
lympho-mononuclear region. (B) CD34PE+ cells are included in R1 in the FSC/SSC dot plot. (C) CD34PE+ cells population in R2. (D) CD34FITC+ cells 
are included in R1 in the FSC/SSC dot plot. (E) CD34FITC+ cells population in R3. (F) CD34PE+ cells are included in R6 in the CD45PerCP/SSC 
dot plot. (G) CD34FITC+ cells are included in R6 in the CD45PerCP/SSC dot plot.
Fig. 2. Representative flow cytometric histograms from bone marrow aspirate specimens after HPC mobilization showing a 3-color 
cytofluorometric analysis of the expression of adhesion molecule antigen on CD34+ cell population. The results were estimated as the mean 
fluorescence intensity (MFI). The histograms (A) and (B) are IgG1 FITC and PE controls. (C) CD106, (D) CD135, (E) CD184, (F) CD62L, (G) CD49d, 
(H) CD11a, and (I) CD44 antigen on CD34+ cell population. The gating protocols have been described before.
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Table 3. Characteristics of patients who underwent large volume leukapheresis.
P
N of individuals who underwent LVL           43
Mean weight, kg (range)           70 (40–114)
Type of venous access
   Peripheral           10
   CVC           33
Mean N of LVL procedure performed             2 (1–4)
Mean amount of blood volume collected per session, mL/min (range)        4.44 (3.0–4.91)
Mean total amount of ACD–A infused, mL (range) 1,251.53 (700–2,121)
Mean blood flow rate, mL/min (range)      89.37 (60–110)
Mean duration of procedure, min (range)    338.86 (156–746)
Mean final volume collected, mL (range)    269.42 (168–334)
Mean Hb level before apheresis, g/dL (range)      11.19 (7.8–15.5) P＜0.01
Mean Hb level after apheresis, g/dL (range)      10.51 (7.6–15.1)
Mean WBC level before apheresis, ×106/L (range)      29.91 (5.4–76.0) P=0.760
Mean WBC level after apheresis, ×106/L (range)      29.23 (4.6–75.4) P＜0.01
Mean PL before apheresis, ×109/L (range)      131.5 (17.1–286) 
Mean PL after apheresis, ×109/L (range)        81.1 (15.1–172)
Abbreviations: ACD-A, acid-citrate-dextrose; CVC, central vein catheter; Hb, hemoglobin; LV, large volume leukapheresis; PL, platelets; WBC, 
white blood cells.
CAM and chemokine determination 
BM samples obtained from the iliac crests using heparin 
as the anticoagulant, before and after HPC mobilization, 
were utilized in this study. After MNC separation, the sam-
ples were assessed via flow cytometry within 24 hours after 
collection. Fluorochromes and monoclonal antibodies, name-
ly, CD45 PerCP-cy5.5 (Clone 2D1 Pharmingen), CD34 PE 
(Clone 581 Immunotech), or FITC (Clone 581 Immunotech), 
against such the adhesion molecules studied were added 
to each BM sample. The expression of VCAM-1 (CD106-PE 
IgG1 kappa, Clone 51-10C9 Pharmingen), FLT-3 (CD135-PE, 
IgG1 kappa, Clone 4G8 Pharmingen), CXCR4 (CD184-PE, 
IgG2a kappa, Clone 12G5 Pharmingen), CD44 (CD44-PE 
IgG1 kappa, Clone 515 Pharmingen), L-selectin (CD62L FITC 
IgG1, Clone DREG56 Immunotech), VLA-4 (CD49d FITC 
IgG1, Clone HP2.1, Immunotech), and LFA-1(CD11a FITC 
IgG1, Clone 25.3.1, Immunotech) was analyzed following 
the ISHAGE recommendation of using 3-color fluorescence 
with sequential gating (Fig. 1). Flow cytometric analysis 
was carried out on a standard FACScan (FACSCalibur BD, 
San Jose, CA, USA) instrument. Forward scatter and side 
scatter (SSC) signals were recorded in linear mode and the 
fluorescence signals in logarithmic mode. The threshold for 
positive cells was set with an appropriated isotype control, 
and a minimum of 300,000 events were acquired for analysis 
of adhesion molecules and chemokine staining. A minimum 
of 100 events within the acquisition gate were stored. The 
amount of adhesion molecules expressed on the CD34+ pop-
ulation was calculated using correction of nonspecific fluo-
rescence from the isotype control. The level of expression 
was estimated as the mean fluorescence intensity (MFI) in 
the positive cells. To evaluate the MFI, a histogram plot 
was used after CD34+ cells have been gated on CD34 fluo-
rescence/SSC (Fig. 2). All data were analyzed using Cell 
Quest software (Becton Dickinson, Franklin Lakes, NJ, USA).
Statistical methods
Nonparametric student’s t-test was used to compare the 
2 study populations. Analysis of variance between multiple 
groups was performed using Tukey’s multiple comparison 
test. Results with a P-value ≤0.05 were considered 
significant. Logistic regression method was applied to inves-
tigate the association between the expression of adhesion 
molecules and the yield of CD34+ cells. All statistical analyses 
were performed using the SPSS software (SDSS.1.4, 2001, 
SPSS Inc., Chicago, IL, USA).
RESULTS
Twelve PBSC donors and 36 patients were enrolled in 
this study. All patients and healthy donors underwent mobi-
lization therapy as described before (Table 2). The number 
of CD34+ cells in the PB was determined prior to LVL only 
in patients. The mean number of CD34+ cells in the PB 
before LVL was 101.34/μL (range, 1–647.2). The mean time 
between mobilization chemotherapy and the first day of 
LVL was 12 days (range, 5–21). A total of 43 individuals 
comprising 31 patients and 12 donors underwent LVL. Five 
patients failed to reach the adequate number of CD34+ cells 
in PB; thus, they did not undergo LVL. The mean yield 
of CD34+ cells in the AP was 11.45×106/kg (range, 1.65–
85.52), and it was higher in the patients than in donors 
(13.63±2.88 and 5.82±0.75, respectively; P=0.019). MM pa-
tients showed the highest number of CD34+ cells in the 
collected PBSC (mean, 18.14±5.53). Among all study partic-
ipants who underwent LVL, 31 (25 patients and 6 donors) 
reached a CD34+ cell yield of ≥5×106/kg, and 12 (6 patients 
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Fig. 3. The mean expression of CD106, CD-44, and CD49d on the CD34+ cells assessed in BMA before mobilization and its association with the 
yield of CD34+ cells collected via LVL in both donors and patients.
Fig. 4. Distribution of CD106, CD135, CD11a, CD44, CD49d, and CD184 assessed in mononuclear cells of the BMA, before and after mobilization 
according to the yield of CD34+ cells obtained via LGV.
and 6 donors) reached ≤5×106/kg (Table 2). The characteristics 
of patients who underwent LVL are described in Table 3.
Expression of CAMs and chemokines on the CD34+ cells 
prior to HPC mobilization
We determined the expressions of CD106, CD135, CD184, 
CD44, CD62, CD49d, and Cd11a on the CD34+ cells in 
steady-state BM for both donors and patients. Ours results 
provide evidence that the number of CD44 and CD49d cells 
in steady-state BM differs significantly between donors and 
patients. The mean expression in MFI of CD44 in donors 
and patients was 834.34±47.01 and 874.31±46.56 (P=0.010), 
respectively. Meanwhile, the mean expression of CD49d in 
donors and patients was 495.32±29.57 and 520.84±22.65 
(P=0.002), respectively. For all the groups studied, when 
we analyzed the correlation between CAMs and chemokine 
expression with good and poor yield of CD34+ cells, we 
found a statistically significant difference in CD106 
(P=0.007), CD44 (P=0.027), and CD49d (P=0.014) (Fig. 3). 
Those with poor CD34+ yield presented a higher expression 
of these 3 molecules than those with good CD34+ cell yield. 
Expression of CAMs and chemokines on the CD34+ cells 
after HPC mobilization
We determined the expression of CD106, CD135, CD184, 
CD44, CD62, CD49d, and Cd11a on the CD34+ cells from 
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Table 4. Comparative analysis of CAM expression assessed in BMA 
before and after HPC mobilization, considering good and poor 
yield of CD34+ cells in LVL. The expression of CD106, CD135, 
CD44, CD49d, and CD11a varied before and after mobilization, 
and this was independent of good CD34+ cell yield. Meanwhile, 
CD184 expression before and after mobilization was only different 
among those with a good yield of CD34+ cells (P=0.002).
Adhesion 
molecule
Good and poor yield of 
CD34+ cells
Pre vs. 
post Interaction
CD106 0.080 0.001 0.192
CD135 0.421 0.001 0.840
CD44 0.455 0.011 0.103
CD49d 0.170 0.001 0.736
CD11a 0.525 0.001 0.548
CD184 0.879 0.308 0.002
the BM after HPC mobilization for both donors and patients. 
We found a reduced expression of the following molecules 
after HPC mobilization that was independent of the CD34+ 
yield: CD106 (P=0.001), CD135 (P=0.001), CD44 (P=0.011), 
CD49d (P=0.001), and CD11a (P=0.001) (Fig. 4).
Meanwhile, CD184 expression was not significantly differ-
ent before and after mobilization, indicating that its behavior 
was different. However, for those subjects with better CD34+ 
yield, CD184 expression varied; it was higher in the pre-mo-
bilization (P=0.002) (Table 4) than post-mobilization, where-
as it was not significantly different before and after mobi-
lization among those with worse CD34+ cell yield (P=0.156). 
CD184 expression was higher in steady-state BM cells among 
individuals with successful BM aspiration than those with 
unsuccessful procedure (529.84±54.68 and 496.31±97.51, re-
spectively, P=0.05). 
DISCUSSION
Changes in the PB concentration of CD34+ cells during 
HPC mobilization are the result of dynamic factors including 
the rate of egress of CD34+ cells from the marrow, the 
circulatory volume of CD34+ cell distributed, and the rate 
of CD34+ cells returning to the marrow. CAMs and chemo-
kines are expressed at different levels in the BM before 
and after HPC mobilization. We compared the behavior 
of CAMs and chemokines before and after HPC mobilization 
independent of the CD34+ yield. Expression of the following 
molecules was significantly reduced in the BM after mobi-
lization: CD106 (P=0.001), CD49d (P=0.001), CD11a (P=0.001), 
CD44 (P=0.011), and CD135 (P=0.001). CD106 is constitu-
tively expressed in BM stromal/endothelial cells and certain 
classes of hematopoietic cells (e.g., B cells, follicular, dendritic 
cells, and macrophages). CD 106 and fibronectin are essential 
ligands to CD49d [23]. We found an extremely lower ex-
pression of CD106 in the CD34+ cell population before and 
after mobilization compared with other molecules, and these 
findings are similar to that previously reported in studies 
in which the expression of CD106 was significantly higher 
in the marrow stromal than HPCs [23, 24]. Our study showed 
a reduced CD49d expression in the BM after mobilization. 
CD49d has been implicated in marrow homing and retention 
of hematopoietic stem cells (HSC) owing to the binding 
of endothelial and stromal cells on the BM surface [23-25]. 
Furthermore, studies examining GCSF-mediated HSC mobi-
lization from the marrow, a process that is accompanied 
by significant blood neutrophilia, have shown that its effects 
on the marrow are partly mediated by the downregulation 
of CD106, presumably interrupting CD49d adhesion. Many 
researchers found a reduced activation state and decreased 
expression of CD49d on circulating CD34+ cells compared 
with CD34+ cells residing in the BM [24-26]. Although our 
study has not analyzed the expression of CAMs in the PB 
after HPC mobilization, the reduced CD49d expression on 
CD34+ cells in the BM after mobilization suggests that CD49d 
is critically involved in the regulation of CD34+ cell traffick-
ing, and it is associated with a facilitated egress and circu-
lation of HPCs. These findings are in accordance with the 
previous reports that G-CSF-stimulated HPC mobilization 
results in increased levels of circulating endothelial adhesion 
molecules. [25, 26]. It is possible that an impaired BM micro-
environment does not release proteolytic enzymes in parallel 
amount from neutrophil precursors. This damaged micro-
environment may retain a higher amount of HPCs, partic-
ularly in heavily treated patients. This hypothesis is sup-
ported by the lower CD49d expression after BM mobilization 
in healthy donors than in previously treated patients in our 
study (495.32±29.57 and 520.84±22.65, respectively; P=0.002).
The β2 integrins CD11a and macrophage antigen-1 have 
been reported to play a role in the attachment of CD34 
cells to stromal cells through one of their ligands, that is, 
ICAM-1 CD54 and heparan sulfate [27]. CD11a expression 
was lower in the BM after mobilization than before 
mobilization. We did not find any correlation between good 
yield of CD34+ and CD11a expression. A possible role of 
CD11a and CD18 during mobilization was described by Gunji 
et al. [28], who reported a significantly decreasing number 
of colony-forming units generated compared to that in con-
trols on using anti-CD-11a and anti-CD18 antibodies in a 
co-culture system of CD34+CD33- cells with a stromal layer.
CD44 mediates adhesion of HA to HSC, and its importance 
as an adhesion molecule for HSC has been demonstrated 
[29, 30]. Herein, the mean expression of CD44 in donors 
and patients before mobilization was 834.34±47.01 and 
874.31±46.56, respectively (P=0.010). In the present study, 
CD44 expression was significantly correlated with CD34+ 
yield (P=0.014). CD44 expression was higher among those 
with poor CD34+ yield than those with good yield. Our 
results show that the correlation of CD44 expression in the 
BM before mobilization with CD34+ yield can be related 
to the outcome of cellular migration, suggesting that high 
levels of CD44 lead to a condition where the cells remain 
adhered to the microenvironment, thus leading to a decrease 
in HPC mobilization. Similar to our results, Lee et al. [31] 
found a downregulation of CD44 expression after G-CSF 
administration.
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Fig. 5. Results obtained through logistic regression analysis. The 
chance of poor mobilization increases by approximately 6% with each 
increase of one unit of CD49d and by approximately 4% with each 
increase of one unit of CD44 in the pre-mobilization phase.
FLT3 is produced by stroma cells and is a strong stimulator 
of the lympho-hematopoietic progenitors [32, 33]. Because 
of the relevant involvement of FLT3 in the hematopoiesis 
and to further assess the possible impact of the administration 
of this cytokine in the context of stem cell transplantation, 
we studied the influence of FLT3 to mobilization before 
and after chemotherapy followed by G-CSF administration. 
In both patients and donors, the MFI of CD34+ cells was 
higher before mobilization than after (P=0.001), but we did 
not find any correlation between FLT3 and the yield of 
CD34+ cells collected via LVL. Our results can be explained 
by the downregulation of FLT3 on mobilized CD34+ cells, 
indicating the role of FLT3 in the migration of HPCs. Fukuda 
et al. [32] showed compelling evidence that the FL/FLT3 
axis also regulates to the migration of normal and transformed 
hematopoietic cells and that this effect is mediated through 
the CXCL12/CXCR4 axis. FLT3L is a stem-cell specific 
growth factor that expands and may also mobilize stem cells 
in mice after its administration for 10 days either as a single 
agent or in combination with other molecules such as IL-8 
and G-CSF [33]. Recently, a clinical trial of FLT3L showed 
that its administration for 5 or 10 consecutive days effectively 
mobilizes CD34+ HSCs in healthy donors [34]. 
 The CXCR4 expression on CD34+ cells analyzed in BMA 
before and after mobilization was statistically significantly 
different among individuals with a good yield of CD34+ 
cells (P=0.036). Interestingly, this was not observed among 
those with poor yield (P=0.156). We also found that CD184 
in steady-state BMA was higher among individuals with 
successful LVL than those with unsuccessful procedure 
(529.84±54.68 and 496.31±97.51, respectively; P=0.05). The 
roles of SDF-1 and CXCR4 in BM progenitor cell retention 
and release are well established. Selective antagonism of 
CXCR4 with the pharmacological agent AMD3100 
(plerixafor) rapidly and potently mobilizes BM progenitor 
cells in both animals and humans [35]. Both the release 
of progenitor cells from the BM to the peripheral blood 
and the recruitment and retention of progenitor cells in 
ischemic tissue are regulated by interactions between SDF-1 
and CXCR4. The rationality for our findings is based on 
the functionality of the CXCR4 receptor on HPCs that is 
modulated by several factors as follows: 1) the level of re-
ceptor expression on the cell surface [35-38]; 2) the sulfation 
status of its N-terminus [35-38]; 3) the availability of SDF-1 
[36-38]; 4) the cleavage of the CXCR4 N-terminus on the 
cells and SDF-1 in extracellular space by serine proteases 
and metalloproteinase-9 [36]. Administration of mobilizing 
agents of CD34+ cell leads to the inactivation of the 
SDF-1/CXCR4 axis and downregulation of expression of this 
molecule in the BM, facilitating the egress of HPCs into 
the circulation [36-38]. 
In conclusion, we attempted to determine particular as-
pects of CAMs and chemokines involved in the mobilization 
of CD34+ cells. However, the mechanism of mobilization 
is highly complex and involves adhesion molecules. 
Moreover, the interaction between different matrix metal-
loproteases and the mechanism by which they are activated 
through proteolytic enzymes are not fully understood. We 
believe that CXCR4, VLA-4, CD44, and VCAM-1 are the 
most important molecules involved in HPC mobilization 
because they showed correlation with the CD34+ yield via 
LVL. Determining predictive markers for mobilization ex-
clusively through laboratory methods is difficult. Among 
the molecules studied, CD44 and VLA-4 had the highest 
potentials (Fig. 5). In particular, CD44 expression was sig-
nificantly high in heavily treated patients. Further studies 
are needed to validate our results.
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